RH
Therapeutic Areas
Avata Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVAT-021 | Adult Focal Epilepsy | Phase 2 |
| AVAT-021 (Pediatric) | Pediatric Focal Epilepsy | Preclinical/Phase 1 |
| AVAT-022 | Pediatric Focal Epilepsy | Discovery/Preclinical |
| AVAT-031 | Schizophrenia | Discovery |
| AVAT-041 | Opioid Sparing/Addiction | Discovery |
Leadership Team at Avata Biosciences
JB
Julian Bryson
Executive Chairman & Cofounder
DA
Dr. Andrew Saich
Chief Medical Officer & Cofounder
DV
Dr. Venkat Goskonda
Chief Scientific Officer
GP
Grace Powell
Head of Regulatory Affairs
DC
Dr. Chris Hayes
Head of Intellectual Property
JG
Jim Gillespie
Program Director
DE
Dr. Emma Cheetham
Patent Portfolio Director